Zobrazeno 1 - 10
of 104
pro vyhledávání: '"Charles Butts"'
Autor:
Takaaki Tokito, Oleksii Kolesnik, Jens Sørensen, Mehmet Artac, Martín Lázaro Quintela, Jong-Seok Lee, Maen Hussein, Miklos Pless, Luis Paz-Ares, Lance Leopold, Jeannie Daniel, Mihaela Munteanu, Ayman Samkari, Lu Xu, Charles Butts
Publikováno v:
BMC Cancer, Vol 23, Iss S1, Pp 1-11 (2024)
Abstract Background Pembrolizumab is a first-line therapy for certain patients with advanced/metastatic non-small cell lung cancer (NSCLC). Combining pembrolizumab with other immunotherapies may enhance tumor cell killing and clinical outcomes. Epaca
Externí odkaz:
https://doaj.org/article/778d9a0bf7f040a3adf76b4a236aef6f
Rapid atrophy of cardiac left ventricular mass in patients with non‐small cell carcinoma of the lung
Autor:
Seyyed Mohammad Reza Kazemi‐Bajestani, Harald Becher, Charles Butts, Naveen S. Basappa, Michael Smylie, Anil Abraham Joy, Randeep Sangha, Andrea Gallivan, Peter Kavsak, Quincy Chu, Vickie E. Baracos
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 10, Iss 5, Pp 1070-1082 (2019)
Abstract Background Cancer is a systemic catabolic condition affecting skeletal muscle and fat. We aimed to determine whether cardiac atrophy occurs in this condition and assess its association with cardiac function, symptoms, and clinical outcomes.
Externí odkaz:
https://doaj.org/article/322f3ddbaafa4239a2a91dccd728dc6f
Publikováno v:
Journal of Cancer Epidemiology, Vol 2012 (2012)
The treatment of elderly cancer patients is complicated by many factors. We sought to assess the uptake and tolerance of chemotherapy among patients 75 years and older diagnosed with small cell lung cancer (SCLC) in years 2004–2008 in Alberta, Cana
Externí odkaz:
https://doaj.org/article/857462ce233943d8ad7edc4ef8e56660
Autor:
Katie Vines, Mark Ward, Charles Butts, Thomas Capasso, Andrew Bright, Yann-Leei Lee, Nathan Polite, Christopher Kinnard, Jon Simmons, Carl Maltese, Ashley Williams, Maryann Mbaka
Publikováno v:
The American Surgeon. :000313482311616
Traumatic aortic injuries in children and adolescents are rare, and even more rare are blunt traumatic injury to the abdominal aorta in this population. Therefore, there are few reports discussing the presentation and repair of such injuries, especia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d68da25deace16168d1f6eeba0acd6f
https://doi.org/10.1177/00031348231161670
https://doi.org/10.1177/00031348231161670
Autor:
Joanna Wojcik-Tomaszewska, Leora Horn, Gregory A. Otterson, Lucio Crinò, Suresh S. Ramalingam, Marina Chiara Garassino, Adam Pluzanski, Hossein Borghaei, John R. Penrod, Ang Li, Scott J. Antonia, Julie R. Brahmer, Marco Angelo Burgio, Charles Butts, Shruti Agrawal, Alexander Drilon, David Planchard, Laura Q.M. Chow, Javier de Castro Carpeño, Scott N. Gettinger
Publikováno v:
The Lancet Oncology. 20:1395-1408
Summary Background Phase 3 clinical data has shown higher proportions of patients with objective response, longer response duration, and longer overall survival with nivolumab versus docetaxel in patients with previously treated advanced non-small-ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23fbf89e0595c489dc1c013caff2a45b
https://doi.org/10.1016/s1470-2045(19)30407-3
https://doi.org/10.1016/s1470-2045(19)30407-3
Rapid atrophy of cardiac left ventricular mass in patients with non‐small cell carcinoma of the lung
Autor:
Charles Butts, Randeep Sangha, Naveen S. Basappa, Andrea Gallivan, Peter A. Kavsak, Quincy Chu, Vickie E. Baracos, Seyyed Mohammad Reza Kazemi-Bajestani, Michael Smylie, Harald Becher, Anil Abraham Joy
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle
Journal of Cachexia, Sarcopenia and Muscle, Vol 10, Iss 5, Pp 1070-1082 (2019)
Journal of Cachexia, Sarcopenia and Muscle, Vol 10, Iss 5, Pp 1070-1082 (2019)
Background Cancer is a systemic catabolic condition affecting skeletal muscle and fat. We aimed to determine whether cardiac atrophy occurs in this condition and assess its association with cardiac function, symptoms, and clinical outcomes. Methods T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3933e62b280500109b80d0f5213acde9
http://europepmc.org/articles/PMC6818459
http://europepmc.org/articles/PMC6818459
Autor:
J. Jolivet, Frances A. Shepherd, F. Romeyer, N. Finn, J. Villeneuve, J. Rothenstein, Rosalyn A. Juergens, A. Faghih, S. Owen, Catherine Labbé, Caroline Mariano, Charles Butts, M.N. Reaume, Filippa Pettersson
Publikováno v:
Current Oncology
Volume 25
Issue 6
Pages 4287-392
Volume 25
Issue 6
Pages 4287-392
Nivolumab was the first immuno-oncology agent available for the treatment of lung cancer in Canada. In the present study, we evaluated the real-world benefit of nivolumab in Canadian patients with lung cancer. Patients included in the cohort were ide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2a1b63762501b05e76926fd8f9c8c1b
https://doi.org/10.3747/co.25.4287
https://doi.org/10.3747/co.25.4287
Autor:
Markus Wohlleber, Hossein Borghaei, Scott N. Gettinger, Everett E. Vokes, Wilfried Enst Erich Eberhardt, David M. Waterhouse, Enriqueta Felip, Charles Butts, Marco Angelo Burgio, Laura Q.M. Chow, David R. Spigel, Osvaldo Arén Frontera, Miriam Alonso Garcia, Joanna Wojcik-Tomaszewska, Manuel Domine, Scott J. Antonia, Fabrice Barlesi, Rita Chiari, Adam Pluzanski, S. Marimuthu, Grzegorz Czyzewicz, Ang Li, Lucio Crinò, David E. Gerber, Julie R. Brahmer, Neal Ready, Oscar Arrieta, Marina Chiara Garassino, Bruno Coudert, Javier de Castro Carpeño
Publikováno v:
Scientia
J Clin Oncol
J Clin Oncol
PURPOSE Immunotherapy has revolutionized the treatment of advanced non–small-cell lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab showed an improvement in overall survival (OS) and favorable safety versus d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d89b8198e8ce6230aa2c1dd4a7f7a11b
https://hdl.handle.net/11351/7634
https://hdl.handle.net/11351/7634
Autor:
Charles Butts, Mustapha Tehfe, Barbara Melosky, Randeep Sangha, Z. Poonja, Z. Xu, A.M.Y. Chan, Rosalyn A. Juergens, Normand Blais, Ming-Sound Tsao, Jason Agulnik, Vera Hirsh, Paul B. Card, D.G. Bebb, G. Liu, Ronald L. Burkes, Roula Albadine, Parneet Cheema, Diana N. Ionescu, W. Morzycki, Mark Vincent
Publikováno v:
Current Oncology
Volume 25
Issue 5
Pages 4379-328
Volume 25
Issue 5
Pages 4379-328
Inhibition of the anaplastic lymphoma kinase (alk) oncogenic driver in advanced non-small-cell lung carcinoma (nsclc) improves survival. In 2015, Canadian thoracic oncology specialists published a consensus guideline about the identification and trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f2c7434e77c15743388594d28da90ed
https://doi.org/10.3747/co.25.4379
https://doi.org/10.3747/co.25.4379
Autor:
Scott N. Gettinger, Neal Ready, Oscar Arrieta, Charles Butts, Marco Angelo Burgio, Diane Healey, David M. Waterhouse, David R. Spigel, Marina Chiara Garassino, Julie R. Brahmer, Ang Li, O. Aren Frontera, George R. Blumenschein, Everett E. Vokes, S.J. Antonia, Enriqueta Felip, Martin Steins, Esther Holgado, Manuel Domine, L. Crinò, Leora Horn, Laura Q.M. Chow, Fabrice Barlesi, Justin F. Gainor, Bruno Coudert, William J. Geese
Publikováno v:
Annals of Oncology. 29:959-965
Background Long-term data with immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) are limited. Two phase III trials demonstrated improved overall survival (OS) and a favorable safety profile with the anti-programmed death-1 antibody n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0599d39611fb99fb86553b2241a1b0c3
https://doi.org/10.1093/annonc/mdy041
https://doi.org/10.1093/annonc/mdy041